SourceBio International: Back with a Bang
SourceBio International (SBI) has made a huge impact on its return to public markets. It reported a 139% rise in fiscal 2020 (FY20) reported revenues to £50.7mln from £21.2mln and underlying earnings (EBITDA) of £14mln, vs £3mln in FY19. Growth was driven largely on its rapid mobilisation of resources to create a new fourth division, infectious disease testing services.
We estimate that the current scale-up provides a peak capacity for up to £9mln revenues per month, prospects for sustained penetration in public and private testing markets, and to cater for evolving testing requirements. Equally, SBI is set to respond to the anticipated tsunami of neglected cases requiring diagnostics, research & development (R&D) support via its Stability Storage segment, and Genomics services, related to non-COVID care once a recovery begins, which should facilitate a turnaround in its other three core divisions.
Quick facts: SourceBio International PLC
Price: 182 GBX
Market Cap: £135.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SourceBio International PLC named herein, including the promotion by the Company of SourceBio International PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE